AI assistant
Ventripoint Diagnostics Ltd. — Regulatory Filings 2020
Jun 4, 2020
45675_rns_2020-06-04_3167f92d-0b67-4830-b34b-f1acc1e5f121.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
FORM 51-102F3 MATERIAL CHANGE REPORT
1. Name and Address of Company
Ventripoint Diagnostics Ltd. (the " Company ") 2 Sheppard Ave. E. Suite 605 Toronto, ON M2N 5Y7
2. Date of Material Change
June 1, 2020.
3. News Release
On June 3, 2020, a news release was issued and disseminated through the facilities of a recognized newswire service.
4. Summary of Material Change
The material change is fully described in the Company’s press release which is attached as Schedule “A” and is incorporated herein.
5. Full Description of Material Change
A description of the material change is contained under Item 4.
6. Reliance on subsection 7.1(2) of National Instrument 51-102
The report is not being filed in reliance on section 7.1(2) of National Instrument 51-102.
7. Omitted Information
No information has been omitted.
8. Executive Officer
The name of the executive officer of the Company who is knowledgeable about the material change and this report is:
Dr. George Adams, Chief Executive Officer Tel: (519) 803-6937 Email: [email protected]
9. Date of Report
June 4, 2020.
SCHEDULE “A” PRESS RELEASE
==> picture [169 x 57] intentionally omitted <==
Ventripoint Announces Appointment of Chief Finance Officer
Toronto, Ontario, June 3, 2020 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) wishes to announce that Victor Hugo has been appointed the CFO of Ventripoint pursuant to a consulting agreement with Marrelli Support Services Inc.
As previously announced, Ellen Briant resigned as CFO of the Corporation in December, 2019. Mr. George Adams has been Acting CFO. The Board of Directors would like to thank Ellen Briant for her many years of excellent service and for assisting in the transition of all accounting and CFO functions to Mr. Hugo, as well as completing the annual financial audit, which was recently filed for the year ending December 31, 2019.
Mr. Hugo is a senior financial analyst at Marrelli Support Services Inc., providing CFO, accounting, regulatory compliance, and management advisory services to numerous issuers on the TSX, TSX-Venture and other Canadian and US exchanges. His public company experience includes preparation of financial statements, initial public offerings and business combinations transactions. He serves as Chief Financial Officer to a number of junior companies listed on the TSX Venture and Canadian Securities Exchanges. Previously, he was the head of the Finance departments at Barrick Gold’s Hemlo operation (2016 – 2017) and Nystar’s Myra Falls mine (2013 – 2016). Mr. Hugo is a CPA, CMA and holds a Bachelors of Commerce with Honours specializing in Accounting and Cost and Management Accounting from Potchefstroom University in South Africa.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information, please contact: Dr. George Adams, Executive-Chaiman, Telephone: (519) 803-6937 Email: [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.